These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2441573

  • 1. CSF-amine metabolites in depression, dementia and in controls.
    Gjerris A, Werdelin L, Gjerris F, Sørensen PS, Rafaelsen OJ, Alling C.
    Acta Psychiatr Scand; 1987 Jun; 75(6):619-28. PubMed ID: 2441573
    [Abstract] [Full Text] [Related]

  • 2. CSF concentration gradients of monoamine metabolites in patients with hydrocephalus.
    Malm J, Kristensen B, Ekstedt J, Wester P.
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1026-33. PubMed ID: 7522267
    [Abstract] [Full Text] [Related]

  • 3. Monoamine metabolites in CSF and suicidal behavior.
    Träskman L, Asberg M, Bertilsson L, Sjöstrand L.
    Arch Gen Psychiatry; 1981 Jun; 38(6):631-6. PubMed ID: 6166274
    [Abstract] [Full Text] [Related]

  • 4. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
    Yoshino K.
    No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264
    [Abstract] [Full Text] [Related]

  • 5. CSF monoamine metabolites in chronic pain.
    France RD, Urban BJ, Pelton S, Kilts CD, Hong JS, Nemeroff CB.
    Pain; 1987 Nov; 31(2):189-198. PubMed ID: 2448727
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Monoamine metabolites in ventricular CSF of children with posterior fossa tumors: correlation with tumor histology and cognitive functioning.
    Varela M, Alexiou GA, Liakopoulou M, Papakonstantinou E, Pitsouni D, Alevizopoulos GA.
    J Neurosurg Pediatr; 2014 Apr; 13(4):375-9. PubMed ID: 24559277
    [Abstract] [Full Text] [Related]

  • 8. CSF neurotransmitter metabolites and neuropsychiatric symptomatology in patients with normal pressure hydrocephalus.
    Markianos M, Lafazanos S, Koutsis G, Sfagos C, Seretis A.
    Clin Neurol Neurosurg; 2009 Apr; 111(3):231-4. PubMed ID: 19046799
    [Abstract] [Full Text] [Related]

  • 9. Comparative evaluation of 5-HIAA (5-hydroxy indoleacetic acid) and HVA (homovanillic acid) in infantile hydrocephalus.
    Gopal SC, Pandey A, Das I, Gangopadhyay AN, Upadhyaya VD, Chansuria JP, Singh TB.
    Childs Nerv Syst; 2008 Jun; 24(6):713-6. PubMed ID: 18075745
    [Abstract] [Full Text] [Related]

  • 10. CSF amine metabolites and depression.
    Peabody CA, Faull KF, King RJ, Whiteford HA, Barchas JD, Berger PA.
    Psychiatry Res; 1987 May; 21(1):1-7. PubMed ID: 2440071
    [Abstract] [Full Text] [Related]

  • 11. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
    Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, Rubinow DR, Sunderland T.
    Biol Psychiatry; 1991 Jun 01; 29(11):1110-8. PubMed ID: 1714776
    [Abstract] [Full Text] [Related]

  • 12. Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence.
    Ogawa S, Tsuchimine S, Kunugi H.
    J Psychiatr Res; 2018 Oct 01; 105():137-146. PubMed ID: 30219563
    [Abstract] [Full Text] [Related]

  • 13. CSF amine metabolites in depression.
    Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS.
    Biol Psychiatry; 1992 Jan 15; 31(2):112-8. PubMed ID: 1371076
    [Abstract] [Full Text] [Related]

  • 14. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD, Sourkes TL, Fang TY, Young SN, Gauthier SG, Missala K.
    Neurology; 1979 Aug 15; 29(8):1157-61. PubMed ID: 37460
    [Abstract] [Full Text] [Related]

  • 15. CSF monoamine metabolites, depression, and suicide.
    Asberg M, Bertilsson L, Mårtensson B.
    Adv Biochem Psychopharmacol; 1984 Aug 15; 39():87-97. PubMed ID: 6205566
    [No Abstract] [Full Text] [Related]

  • 16. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y, Bardgett ME, Csernansky JG.
    J Clin Psychopharmacol; 1997 Feb 15; 17(1):11-4. PubMed ID: 9004051
    [Abstract] [Full Text] [Related]

  • 17. Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment.
    Beckmann H, Waldmeier P, Lauber J, Gattaz WF.
    J Neural Transm; 1983 Feb 15; 57(1-2):103-10. PubMed ID: 6194254
    [Abstract] [Full Text] [Related]

  • 18. Reduction of biogenic amine levels in the Rett syndrome.
    Zoghbi HY, Percy AK, Glaze DG, Butler IJ, Riccardi VM.
    N Engl J Med; 1985 Oct 10; 313(15):921-4. PubMed ID: 2412119
    [Abstract] [Full Text] [Related]

  • 19. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels.
    Gibbons RD, Davis JM.
    Acta Psychiatr Scand; 1986 Jul 10; 74(1):8-12. PubMed ID: 2429500
    [Abstract] [Full Text] [Related]

  • 20. Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites.
    Hovi-Viander M, Kanto J, Scheinin H, Scheinin M.
    Br J Clin Pharmacol; 1985 Nov 10; 20(5):492-6. PubMed ID: 2416331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.